Argentum Medical’s Silverlon for Radiation Dermatitis Designated a Breakthrough Device

Argentum Medical has received the FDA’s Breakthrough Device designation for its Silverlon wound and burn contact dressings.

The antimicrobial dressings, which are intended to prevent infection in wound or burn victims, may be used for radiation dermatitis and cutaneous radiation injuries that do not require skin grafting, the Geneva, Ill.-based company said.  

Argentum received a $10 million development contract from the Biomedical Advanced Research and Development Authority to develop the dressings.